Medpace Holdings, INC Form 4 insider transactions

Medpace Holdings Director Brian T. Carley reports the acquisition of a stock option grant, with vesting contingent on continued service.

Medpace Holdings CEO August J. Troendle acquired 20,000 employee stock options and 10,000 restricted stock units, reflecting continued investment in the company.

Medpace Holdings Inc. reports insider transactions involving common stock, stock options, and restricted stock units by General Counsel & Corp. Secy. Stephen P. Ewald.

Medpace Holdings, Inc. reports that Executive Vice President Susan E. Burwig was granted stock options and restricted stock units.

Medpace Holdings CFO Kevin M. Brady reports significant transactions including the acquisition of common stock and the exercise of stock options.

Cornelius P. McCarthy III, a Director at Medpace Holdings, Inc., acquired 29 shares of common stock on March 31, 2026, through the vesting of restricted stock units.

Medpace Holdings Director Robert O. Kraft reported the acquisition of 33 shares of common stock on March 31, 2026, through restricted stock units.

Brian T. Carley, a Director at Medpace Holdings, Inc., acquired 36 shares of common stock through the vesting of restricted stock units.

Medpace Holdings' Executive VP of Operations, Susan E. Burwig, exercised 12,000 stock options and acquired common stock.

Medpace Holdings President Jesse J. Geiger exercised stock options and subsequently sold 31,707 shares of common stock under a pre-arranged plan.

Medpace Holdings Director Cornelius P. McCarthy III acquired 49 shares of common stock through the vesting of restricted stock units.

Medpace Holdings Director Robert O. Kraft converted 56 restricted stock units into common stock, increasing his direct ownership to 889 shares.

Medpace Holdings Director Brian T. Carley converted 62 restricted stock units into common stock on December 31, 2025, increasing his direct beneficial ownership to 26,281 shares.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, exercised 10,000 employee stock options at $107.93 per share.

Medpace Holdings, Inc. CEO August J. Troendle reported the sale of 668 shares of common stock at a weighted average price of $590.69.

Medpace Holdings Executive VP of Operations, Susan E. Burwig, exercised and sold 10,000 shares of common stock under a pre-arranged plan.

Medpace Holdings CEO August J. Troendle reported selling over $17 million worth of company common stock in early December 2025.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III was granted 113 restricted stock units, vesting quarterly through December 2026.

Medpace Holdings, Inc. Director Robert O. Kraft received a grant of 130 restricted stock units, vesting quarterly throughout 2026.

Medpace Holdings, Inc. Director Brian T. Carley was granted 143 restricted stock units, vesting over four installments through December 2026.

Medpace Holdings CEO August J. Troendle reported direct sales of 56,482 shares of common stock totaling approximately $34.09 million in late November 2025.

Medpace Holdings, Inc. CEO August J. Troendle sold 101,417 shares of common stock for approximately $61.9 million in pre-arranged transactions.

Medpace Holdings' Executive VP of Operations, Susan E. Burwig, filed a Form 4 indicating a planned sale of 20,000 shares of common stock on November 24, 2025, for an average price of $609.15, executed under a Rule 10b5-1 plan.

Medpace Holdings, Inc. CFO Kevin M. Brady exercised stock options and subsequently sold a portion of the acquired shares, while also gifting a small number of shares.

Medpace Holdings CEO August J. Troendle sold 28,688 shares of common stock for approximately $17 million through a pre-arranged trading plan.

Medpace Holdings CEO August J. Troendle sold over 31,000 shares of common stock in mid-November 2025 through a pre-arranged 10b5-1 plan.

Director Robert O. Kraft exercised options at $54.99 and sold 6,472 shares at a $591.85 weighted average on November 14, 2025, leaving 833 shares owned.

CEO August J. Troendle sold 20,794 Medpace shares at weighted averages of $595.26 and $591 within price ranges of $590.00–$600.51 and $590.00–$593.185, and now holds 893,368 direct shares plus 4,733,019 indirectly.

Medpace Holdings CEO August J. Troendle reported the sale of 10,440 shares of common stock over two days in November 2025.

A Medpace Holdings, Inc. executive sold 18,000 shares of common stock for $605 per share on November 11, 2025, as part of a pre-arranged plan.